What the Research Shows

A 2025 systematic review in HSS Journal searched the medical literature for BPC-157 studies relevant to muscles, tendons, ligaments and bones. Of 36 studies that qualified, 35 were preclinical and just one involved patients. That ratio sums up the state of the field.

Tendons and Ligaments

• Achilles tendon (J Orthop Res, 2003): rats with a surgically cut Achilles tendon received BPC-157 or saline. Treated animals showed better walking function, stronger tendons and more organised healing tissue.
• Tendon cells (J Appl Physiol, 2011): in cell culture, tendon fibroblasts spread out and moved faster and coped better with oxidative stress.

Blood Vessels

In the 2017 Journal of Molecular Medicine study, rats with a tied-off leg artery recovered blood flow faster with BPC-157, and more small vessels were found in the muscle. Cell work linked this to the VEGFR2 receptor and nitric oxide production.

The Gut

Protecting the digestive tract was the original focus. Rat studies from Zagreb report fewer ulcers caused by alcohol or painkillers, and faster healing of experimental colitis and fistulas. A 2012 review in Current Medicinal Chemistry, focused on ulcerative colitis, summarises this work. Controlled trials in patients with bowel disease have not been published in full.

Safety Testing in Animals

In 2020 a team in Xi'an, China, reported standard toxicity tests in mice, rats, rabbits and dogs in Regulatory Toxicology and Pharmacology. They found no serious toxicity, only mild irritation at the injection site, no genetic or embryo-fetal toxicity, and a reversible drop in creatinine at the highest dose in dogs. This is useful groundwork, but animal safety does not guarantee safety in people.

Studies in Humans

A 2025 narrative review in Current Reviews in Musculoskeletal Medicine counted only three human pilot studies. All came from the same private clinic in the United States:

• Knee pain (2021): a telephone survey of 16 patients who had knee injections. Of 12 who received BPC-157 alone, 11 said their pain improved. There was no control group and no objective measurements.
• Interstitial cystitis (2024): 12 women received a single set of bladder wall injections during cystoscopy. Ten reported complete relief of symptoms and no side effects were recorded. Again there was no placebo group.
• Intravenous safety (2025): two adults received infusions of 10 mg and 20 mg on consecutive days. Blood tests for the heart, liver, kidneys, thyroid and glucose did not change.

These reports are interesting, but they are very small, uncontrolled and open to bias. The authors of both 2025 reviews concluded that BPC-157 should be regarded as investigational.

What We Still Do Not Know

• Whether any effect seen in rats happens in humans at all.
• What a safe dose would be, and what happens with long-term use.
• Whether it could encourage the growth of unwanted tissue, a theoretical concern with anything that promotes blood vessel growth.
• Whether independent labs can reproduce the main animal results.

References

1. Sikirić P, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87:313-327. PMID 8298609
2. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21:976-983. PMID 14554208
3. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Inflammopharmacology. 2006;14:214-221. PMID 17186181
4. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774-780. PMID 21030672
5. Sikiric P, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012;19:126-132. PMID 22300085
6. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95:323-333. PMID 27847966
7. Seiwerth S, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24:1972-1989. PMID 29998800
8. Xu C, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID 32334036
9. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27:8-13. PMID 34324435
10. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717
11. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30:12-17. PMID 39325560
12. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20-24. PMID 40131143
13. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21:485-495. PMID 40756949
14. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18:611-619. PMID 40789979